After six years at Apellis, Chief Operating Officer Adam Townsend is saying goodbye to take on his first CEO job. The veteran ...

Notch Therapeutics is making “significant” layoffs to conserve its cash while the cell therapy biotech seeks out new partners ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

A new study of nerve cells affected by Huntington’s disease (HD) reveals that the disease-causing gene slowly expands over ...

One of the biggest stories of last year was Lykos Therapeutics’ failure to get its MDMA candidate over the finish line for ...

While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

In an early look at its annual earnings report, Guardant Health posted revenue gains of 31%—with the $737 million total ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...